Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Liabilities from Discontinued Operations (2025)

Adma Biologics' Liabilities from Discontinued Operations history spans 1 years, with the latest figure at 2647000.0 for Q4 2025.

  • For Q4 2025, Liabilities from Discontinued Operations changed N/A year-over-year to 2647000.0; the TTM value through Dec 2025 reached 2647000.0, changed N/A, while the annual FY2025 figure was 2647000.0, N/A changed from the prior year.
  • Liabilities from Discontinued Operations reached 2647000.0 in Q4 2025 per ADMA's latest filing.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 2647000.0 in Q4 2025 to a low of 2647000.0 in Q4 2025.